JP2014523420A5 - - Google Patents

Download PDF

Info

Publication number
JP2014523420A5
JP2014523420A5 JP2014516016A JP2014516016A JP2014523420A5 JP 2014523420 A5 JP2014523420 A5 JP 2014523420A5 JP 2014516016 A JP2014516016 A JP 2014516016A JP 2014516016 A JP2014516016 A JP 2014516016A JP 2014523420 A5 JP2014523420 A5 JP 2014523420A5
Authority
JP
Japan
Prior art keywords
methyl
oxo
azaspiro
oxa
imidazole
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014516016A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014523420A (ja
JP5969016B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/042607 external-priority patent/WO2012174342A1/en
Publication of JP2014523420A publication Critical patent/JP2014523420A/ja
Publication of JP2014523420A5 publication Critical patent/JP2014523420A5/ja
Application granted granted Critical
Publication of JP5969016B2 publication Critical patent/JP5969016B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014516016A 2011-06-17 2012-06-15 Trpv4拮抗薬 Expired - Fee Related JP5969016B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161498104P 2011-06-17 2011-06-17
US61/498,104 2011-06-17
PCT/US2012/042607 WO2012174342A1 (en) 2011-06-17 2012-06-15 Trpv4 antagonists

Publications (3)

Publication Number Publication Date
JP2014523420A JP2014523420A (ja) 2014-09-11
JP2014523420A5 true JP2014523420A5 (enExample) 2015-07-16
JP5969016B2 JP5969016B2 (ja) 2016-08-10

Family

ID=47357483

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014516016A Expired - Fee Related JP5969016B2 (ja) 2011-06-17 2012-06-15 Trpv4拮抗薬

Country Status (5)

Country Link
US (1) US9487507B2 (enExample)
EP (1) EP2720546B1 (enExample)
JP (1) JP5969016B2 (enExample)
ES (1) ES2571409T3 (enExample)
WO (1) WO2012174342A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2595606T3 (es) 2011-06-17 2017-01-02 Glaxosmithkline Intellectual Property (No. 2) Limited Antagonistas TRPV4
JO3154B1 (ar) 2011-06-17 2017-09-20 Glaxosmithkline Llc عوامل مضادة لـ trpv4
EP2832731A4 (en) 2012-03-27 2015-08-19 Shionogi & Co AROMATIC HETEROCYCLIC CHAIN 5-CORE DERIVED DERIVATIVE HAVING TRPV4 INHIBITORY ACTIVITY
WO2015046193A1 (ja) 2013-09-25 2015-04-02 塩野義製薬株式会社 Trpv4阻害活性を有する芳香族複素環式アミン誘導体
WO2015136947A1 (en) 2014-03-14 2015-09-17 Raqualia Pharma Inc. Azaspiro derivatives as trpm8 antagonists
RU2018144774A (ru) * 2016-05-19 2020-06-19 Глэксосмитклайн Интеллекчуал Проперти (Но.2) Лимитед Антагонист trpv4
US10968209B2 (en) 2016-05-19 2021-04-06 Glaxosmithkline Intellectual Property (No.2) Limited TRPV4 antagonist
WO2018185701A1 (en) * 2017-04-06 2018-10-11 Glaxosmithkline Intellectual Property (No.2) Limited Trpv4 antagonists as antitussive agents
CN115427409B (zh) 2020-04-30 2025-02-25 拉夸里亚创药株式会社 作为trpv4拮抗剂的嘧啶-4(3h)-酮衍生物
CN111704613B (zh) * 2020-06-23 2021-07-06 中国人民解放军军事科学院军事医学研究院 咪唑类衍生物及其作为trpv4抑制剂的用途
TW202216143A (zh) 2020-07-16 2022-05-01 日商拉夸里亞創藥股份有限公司 作為眼疾病的治療藥之trpv4抑制藥
CA3261160A1 (en) 2022-07-08 2024-01-11 Actio Biosciences Inc COMPOUNDS AND THERAPEUTIC METHODS
CN120435476A (zh) * 2023-04-18 2025-08-05 河北乌图药业有限公司 化合物及其在慢性乙型肝炎、肝纤维化、肝癌的治疗中的应用
WO2024217452A1 (zh) * 2023-04-18 2024-10-24 河北乌图药业有限公司 化合物及其在慢性乙型肝炎、肝纤维化、肝癌的治疗中的应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE482945T1 (de) * 1998-05-26 2010-10-15 Chugai Pharmaceutical Co Ltd Heterozyklische indolderivate und mono- oder diazaindol-derivate
EP1644358A2 (en) * 2003-07-16 2006-04-12 Neurogen Corporation Biaryl piperazinyl-pyridine analogues
TW200819457A (en) * 2006-08-30 2008-05-01 Actelion Pharmaceuticals Ltd Spiro antibiotic derivatives
EP2118097A1 (en) * 2007-02-01 2009-11-18 Glaxo Group Limited 1-oxa-3-azaspiro[4,5]decan-2-one derivatives for the treatment of eating disorders
WO2008092887A1 (en) * 2007-02-01 2008-08-07 Glaxo Group Limited I-oxa-3-azaspiro (4.5) decan-2-one and 1-oxa-3, 8-diazaspiro (4.5) decan-2-one derivatives for the treatment of eating disorders
GB0707934D0 (en) * 2007-04-24 2007-05-30 Glaxo Group Ltd Chemical compounds
EP2185538A2 (en) * 2007-08-09 2010-05-19 Abbott Laboratories Tetrahydropyridine carboxamide derivatives as trpvl antagonists
TW200944520A (en) * 2008-01-29 2009-11-01 Glaxo Group Ltd Spiro compounds as NPY Y5 receptor antagonists
WO2010011914A1 (en) * 2008-07-25 2010-01-28 Smithkline Beecham Corporation Trpv4 antagonists
JP2012006837A (ja) * 2008-09-30 2012-01-12 Mochida Pharmaceut Co Ltd 2−インドールアクリルアミド類縁体
ES2595606T3 (es) 2011-06-17 2017-01-02 Glaxosmithkline Intellectual Property (No. 2) Limited Antagonistas TRPV4
JO3154B1 (ar) 2011-06-17 2017-09-20 Glaxosmithkline Llc عوامل مضادة لـ trpv4

Similar Documents

Publication Publication Date Title
JP2014523420A5 (enExample)
JP2018118992A5 (enExample)
JP2011252024A5 (enExample)
HRP20180546T1 (hr) Supstituirani benzilindazoli za uporabu kao inhibitori bub1 kinaze za liječenje hiperproliferativnih bolesti
JP2012525431A5 (enExample)
JP2020515575A5 (enExample)
JP2017510554A5 (enExample)
JP2008513514A5 (enExample)
JP2012505881A5 (enExample)
JP2010502716A5 (enExample)
HRP20160359T1 (hr) Derivati kinazolindiona, njihovo dobivanje i njihove terapijske primjene
JP2011500806A5 (enExample)
JP2010510319A5 (enExample)
JP2006500393A5 (enExample)
JP2019530695A5 (enExample)
JP2013528204A5 (enExample)
JP2017537948A5 (enExample)
IL258577A (en) 2,4-dihydroxy-nicotinamides as apj agonists
HRP20150837T1 (hr) Heteroaril supstituirani pirolo[2,3-b]piridini i pirolo[2,3-b]pirimidini kao inhibitori janus kinaze
JP2018530591A5 (enExample)
JP2013517283A5 (enExample)
JP2008535871A5 (enExample)
JP2010510242A5 (enExample)
JP2013519724A5 (enExample)
RU2009148304A (ru) Модуляторы гидролазы амидов жирных кислот на основе гетероарилзамещенной мочевины